Case Report: Persistent Pulmonary Hypertension of the Newborn and Narrowing of the Ductus Arteriosus After Topical Use of Non-Steroidal Anti-Inflammatory During Pregnancy

Duc, Kévin Le; Gilliot, Sixtine; Baudelet, Jean Benoit; Mur, Sébastien; Boukhris, Mohamed Riadh; Domanski, Olivia; Odou, Pascal; Storme, Laurent

doi:10.3389/fphar.2021.756056

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diclofenac is the representative of the class that shows the greatest power to inhibit prostaglandin E2 (PGE2) production both in vitro and in vivo. Diclofenac is a low molecular weight molecule that easily crosses membranes, with an average maternal/fetus drug ratio < 1, concluding that over time it can accumulate in the fetal tissue [96,97]. Metamizole sodium, withdrawn from the US but still available in Europe and Latin America, has been studied for its toxic effect on the fetus.…”

Section: Non-steroidal Anti-inflammatory Agentsmentioning

confidence: 99%

The Main Changes in Pregnancy—Therapeutic Approach to Musculoskeletal Pain

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: During pregnancy, women undergo various physiological and anatomical changes that are accentuated as the pregnancy progresses, but return to their previous state a few weeks/months after the pregnancy. However, a targeted therapeutic approach is needed. Most of the time, during this period, these changes precipitate the appearance of pain, musculoskeletal pain being the most common. Pregnant women should avoid treating musculoskeletal pain with medication and should choose alternative and complementary methods. Exercise along with rest is the basis for treating chronic musculoskeletal pain. Side effects of physical therapy are rare and, in addition, it is not contraindicated in pregnant women. The benefits of this type of treatment in combating pain far outweigh the risks, being an easy way to improve quality of life. The objective of this article is to discuss the management of musculoskeletal pain during pregnancy, to identify the main musculoskeletal pain encountered in pregnant women along with drug treatment, and to expose the beneficial effects of alternative and complementary methods in combating pain. Materials and Methods: A literature search was conducted using medical databases, including PubMed, Google Scholar, and ScienceDirect, using the keywords “changes of pregnancy”, “musculoskeletal pain”, “pregnancy pain”, “pain management”, “pharmacological approach”, “alternative and complementary treatment” and specific sites. Information was collected from studies whose target population included pregnant women who complained of musculoskeletal pain during the 9 months of pregnancy; pregnant women with other pathologies that could increase their pain were not included in this review. Results: The articles related to the most common non-obstetric musculoskeletal pain in pregnancy along with pharmacological treatment options and alternative and complementary methods for musculoskeletal pain management during pregnancy were selected. Conclusions: The results were used to guide information towards the safest methods of therapy but also to raise awareness of the treatment criteria in order to compare the effectiveness of existing methods. Treatment must consider the implications for the mother and fetus, optimizing non-pharmacological therapeutic options.

show abstract

Section: Non-steroidal Anti-inflammatory Agentsmentioning

confidence: 99%

The Main Changes in Pregnancy—Therapeutic Approach to Musculoskeletal Pain

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, we did not observe a dramatic change in NSAID exposure during pregnancy after this date. Regarding topical use, the complications after maternal exposure are suspected based on case reports describing use of topical diclofenac [ 41 , 42 ]. Our results were in accordance with another French cohort study, describing 60 per 10,000 exposed pregnancies after the sixth month [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: A nationwide cohort study

Louchet,

Collier,

Beeker

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Objective Describe the trends of exposure to harmful drugs during pregnancy over recent years in France. Design Nationwide cohort study. Setting The French National administrative health Data System (SNDS). Population Pregnancies starting between 2013 and 2019 and outcomes corresponding to live births, medical terminations of pregnancy, and stillbirths. Methods Each pregnancy was divided into a preconceptional period of 90 days before conception and three trimesters from conception to birth. Harmful drugs were defined according to their risks to the fetus: teratogenicity or fetotoxicity. Exposure was defined using the critical period during pregnancy for each type of harmful drug: preconceptional period or first trimester for teratogenic drugs and second or third trimesters for fetotoxic drugs. Main outcome measures Prevalence of pregnancies exposed to at least one harmful drug. Results Among 5,253,284 pregnancies, 204,402 (389 per 10,000) pregnancies were exposed to at least one harmful drug during the critical periods: 48,326 (92 per 10,000) pregnancies were exposed to teratogenic drugs during the preconceptional period or the first trimester, and 155,514 (299 per 10,000) pregnancies were exposed to fetotoxic drugs during the second or third trimesters. Teratogenic drugs were mainly retinoids for topical use (44 per 10,000 pregnancies), antiepileptics (13 per 10,000 pregnancies) and statins (13 per 10,000 pregnancies). Fetotoxic drugs were mainly non-steroidal anti-inflammatory drugs (NSAIDs), for systemic (128 per 10,000 pregnancies) and topical use (122 per 10,000 pregnancies). Exposure to teratogenic drugs decreased from the preconceptional period to the first trimester. Exposure to fetotoxic drugs decreased from the second to the third trimester. Between 2013 and 2019, we found a decrease in harmful drug exposure overall, mainly for topical and systemic NSAIDs and for topical retinoids. Conclusions In this nationwide study, about one in 25 pregnancies was exposed to at least one harmful drug, mainly NSAIDs and topical retinoids. Although the prevalence of harmful drug exposure decreased over the study period, NSAID exposure in the second and third trimester remains of concern.

show abstract

“…Mefenamic acid consider as a class of a nonsteroidal anti-inflammatory medicine (NSAID), and owing to the powerful analgesic and anti-inflammatory qualities it has, it has garnered a large amount of interest in recent years. As a consequence of this, it is used extensively in the therapy of a wide variety of unpleasant diseases, including menstrual cramps, rheumatoid arthritis, and osteoarthritis, amongst others (1) . It contains numbing, anti-pyretic, and anti-inflammatory characteristics, at higher concentrations, this molecule reduces inflammation (2) .…”

Section: Highlight Introductionmentioning

confidence: 99%

Método de inyección de flujo sensible a base de neocuproina para la determinación de ácido mefenámico en soluciones acuosas y formulaciones farmacéuticas

Naser Nayef,

Frak Hussain,

Taha

2023

Ars Pharm

View full text Add to dashboard Cite

Introducción:Se presenta un enfoque novedoso y preciso para la estimación del ácido mefenámico (MEF) en formulaciones farmacéuticas y soluciones acuosas, utilizando espectrofotometría de inyección de flujo. Del mismo modo, este método demuestra un alto nivel de sensibilidad y precisión Método: Se basa en la reducción del complejo Cu (II)-2,9DMP a complejo Cu (I)-2,9DMP coloreado, mediante dos pasos de reacción. Sin embargo, en el primer paso se produce la reacción entre la neocuproína y el Cu (ΙΙ) para formar un complejo incoloro de Cu (II) -2,9DMP, y en el segundo paso el ácido mefenámico redujo el complejo incoloro formado a Cu (I) - 2,9DMP con color amarillo anaranjado, se desarrolló y validó el método de inyección de flujo. Resultados: La medición de la densidad óptica de las sustancias amarillo-naranja se realizó a una longitud de onda de 454 nm. Los gráficos de calibración muestran linealidad dentro de los rangos de concentración especificados de 1,00-80,00 μg / ml. El límite de detección (LOD) se determina en 0,360 μg/ml, mientras que el límite de cuantificación (LOQ) se encuentra en 1.093 μg/ml. Conclusiones: la metodología propuesta exhibió atributos notables como rapidez, sensibilidad y confiabilidad, lo que la hace adecuada para la cuantificación precisa de (MEF) en formulaciones farmacéuticas y soluciones acuosas en diversas formulaciones disponibles comercialmente.

show abstract

Case Report: Persistent Pulmonary Hypertension of the Newborn and Narrowing of the Ductus Arteriosus After Topical Use of Non-Steroidal Anti-Inflammatory During Pregnancy

Cited by 5 publications

References 25 publications

The Main Changes in Pregnancy—Therapeutic Approach to Musculoskeletal Pain

The Main Changes in Pregnancy—Therapeutic Approach to Musculoskeletal Pain

Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: A nationwide cohort study

Método de inyección de flujo sensible a base de neocuproina para la determinación de ácido mefenámico en soluciones acuosas y formulaciones farmacéuticas

Contact Info

Product

Resources

About